Minimal change disease cost-effectiveness of therapy

Jump to navigation Jump to search
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Overview

Azathioprine may be cost effective in treating the patients with minimal change disease .

Cost-effectiveness of Therapy

Minimal Change Disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Minimal Change Disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Immunohistology

Electron Microscopy

Electrocardiogram

X-ray

Echocardiorgaphy or Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Minimal change disease cost-effectiveness of therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Minimal change disease cost-effectiveness of therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Minimal change disease cost-effectiveness of therapy

CDC on Minimal change disease cost-effectiveness of therapy

Minimal change disease cost-effectiveness of therapy in the news

Blogs on Minimal change disease cost-effectiveness of therapy

Directions to Hospitals Treating Minimal change disease

Risk calculators and risk factors for Minimal change disease cost-effectiveness of therapy

References

  1. Nolasco F, Cameron JS, Heywood EF, Hicks J, Ogg C, Williams DG (June 1986). "Adult-onset minimal change nephrotic syndrome: a long-term follow-up". Kidney Int. 29 (6): 1215–23. PMID 3747335.

Template:WH Template:WS